Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.47 per share which beat the analyst consensus estimate of $4.31 by 3.71 percent. This is a 10.1 percent increase over earnings of $4.06 per share from the same period last year. The company reported quarterly sales of $2.987 billion which missed the analyst consensus estimate of $3.032 billion by 1.48 percent. This is a 7.83 percent increase over sales of $2.770 billion the same period last year.